Linox Smart S DX PME/Master Study
PME/Master Study of the Linoxsmart S DX ICD Leads
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 12200
- Charite University Hospital Benjamin Franklin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with standard ICD indication
- Be available for follow-up visits on a regular basis at an approved investigational center
Exclusion Criteria:
- Patients with standard ICD contra-indication
- Patients with permanent atrial fibrillation
- Have a life expectancy of less than six months
- Are expecting to receive cardiac surgery within 6 months after enrollment
- Age < 18 years
- Not enrolled in another cardiac clinical investigation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Patients with Linox smart S DX lead
|
ICD lead
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of atrial adequate sensing
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Linox smart S DX related complication-free rate
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 48-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ICD Indication
-
NCT01714921CompletedPatients With an Indication for an ICD Implantation According to the Guidelines
-
NCT00916344CompletedPacemaker Indication
-
NCT03749252CompletedPediatric Patients | Central Nervous System Indication | Body Indication
-
NCT04241757TerminatedIndication for ElectroCardioGram
-
NCT07053631RecruitingIndication for CSF Dynamic Testing | Indication for CSF Infusion Test
-
NCT03358615CompletedIndication of Cesarean Section
-
NCT02498821CompletedIndication for PICC Placement
Clinical Trials on Linox smart S DX
-
NCT02186704Completed
-
NCT01790841CompletedHeart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Sudden Cardiac Death
-
NCT03891329CompletedHeart Failure | Tachyarrhythmia
-
NCT02606916CompletedEsophageal Squamous Cell Carcinoma
-
NCT01809665CompletedSafety of MR (Magnetic Resonance) Conditional CRT-pacemakers and ICDs
-
NCT02569567Unknown
-
NCT05306691Not yet recruitingCaries, Dental | Remineralization | White Spot Lesion
-
NCT04568473Completed
-
NCT04502095CompletedUrinary Tract Infection | Bladder Carcinoma | Refractory Bladder Carcinoma
-
NCT03220022Active, not recruitingAnn Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | AIDS-Related Lymphoma